Paddock Laboratories: The Patent Challenger in the Actavis Case
In the Paddock Laboratories AndroGel settlement, Solvay promised total payments of $12 million to Paddock and $60 million to Par in a deal the Federal Trade Commission challenged as pay-for-delay. The Supreme Court’s account of the agreement describes payments to companies that had challenged the brand’s patent. The Commission alleged that the settlement paid the challengers to abandon that fight and postpone competing. For someone who knows the contracts, the central question is what the money bought: the services described on paper or time without a competing drug.
Paddock and Par Had Different Application Roles
In the Paddock and Par AndroGel settlement, the companies had different application roles: Paddock filed the generic application, while Par shared the patent-litigation costs in return for a share of profits if Paddock won approval. Par did not file an application of its own. The partnership connected the cost of challenging the patent to the profit expected from reaching the market.
AndroGel is a prescription testosterone gel. Solvay applied for approval in 1999, received Food and Drug Administration approval in 2000 and obtained a relevant patent in 2003. Actavis, then known as Watson Pharmaceuticals, applied for a generic version later that year. Paddock filed its own application after that.
Both applicants told the agency that Solvay’s patent was invalid and that their drugs did not infringe it. Solvay sued them for patent infringement.
What the AndroGel Agreement Bought
The parties settled the patent litigation in 2006 with payments and promises to delay generic competition. The Supreme Court described Actavis’s promise to keep its generic off the market until August 31, 2015, unless someone else marketed a generic sooner. It said the other generic manufacturers made roughly similar promises. Actavis also had a separate annual payment arrangement and agreed to promote AndroGel to urologists.
The companies described the money as compensation for services. The Federal Trade Commission alleged that those services had little value and that the payments actually compensated the generic manufacturers for agreeing to stay out of AndroGel’s market. That dispute puts the commercial work behind the contracts at the center of the case: what service was promised, what it was worth and why the brand manufacturer agreed to buy it.
Why Filing First Could Shape Generic Competition
Under the generic approval rules governing this dispute, the first qualifying patent challenger could receive 180 days of generic exclusivity after beginning commercial sales. Actavis held that first-filer position. Paddock filed afterward.
The application offered an abbreviated approval route. A generic manufacturer could rely on the brand drug’s earlier approval by showing the same active ingredients and biological equivalence, avoiding repetition of the brand’s full testing program. But a timely patent-infringement suit usually held approval for 30 months while the patent dispute proceeded.
An approval and a launch were different business events. Actavis obtained Food and Drug Administration approval before settling, yet agreed to wait to sell. The Court explained that later challengers had less to gain because they could not capture the first applicant’s exclusive selling period. Paying the first applicant to wait could therefore remove the competitor best placed to enter quickly without drawing an equally motivated replacement.
The brand would pay its challengers to stay out, and buyers would lose the price competition those challengers might have brought. That was the harm the Court described: the companies could share the benefit of keeping brand prices intact while consumers lost out.
Why the Backup Supply Agreement Mattered to Perrigo
Paddock’s backup supply agreement could also affect a new owner’s incentive to launch a competing drug. The Federal Trade Commission’s August 2011 merger analysis examined that problem when Perrigo proposed acquiring Paddock.
According to the agency, Par had agreed to delay introducing generic AndroGel in exchange for consideration that included payments under that supply agreement. The agreement had since transferred to Paddock. Buying Paddock would make Perrigo a party to it.
Perrigo was itself one of a limited number of suppliers capable of entering the future generic testosterone-gel market promptly. The Commission said the acquisition could give Perrigo and Abbott, which then marketed AndroGel, greater ability to coordinate a delay in Perrigo’s launch.
The proposed remedy would prohibit payments accruing after the supply agreement’s initial term except payments for manufacturing the product. It would also prohibit anticompetitive pay-for-delay arrangements with Abbott concerning testosterone gel. After that term, payment for making the drug could continue. Other payments under the contract could not.
What the Supreme Court Changed
On June 17, 2013, the Supreme Court allowed the Federal Trade Commission’s antitrust challenge to proceed. A payment to delay competition could face scrutiny even if the agreed delay ended before the patent expired.
The Commission had sued Solvay, Actavis, Paddock and Par in 2009. The lower courts dismissed the case because the agreement’s restrictions stayed within the protection the patent could provide. The Supreme Court reversed that result.
The Court called for examining the payment’s size, how it compared with expected litigation costs, whether it paid for services and what other justification supported it. For an employee familiar with the commercial terms, the important evidence reaches beyond the patent to the reasons for the payment itself.
What the Contracts Can Show
We examine the entry restrictions alongside the promised services, their valuation and the payment terms. In an arrangement like Paddock’s, the supply contract and its transfer can also explain how the incentive reaches another company.
The value of services also matters in pharmaceutical enforcement cases involving government price reports. Calling a price concession a service fee can leave Medicare’s reported drug-price benchmark too high. That is a concrete connection between the work behind a contract and false drug-price reporting.
For pharmaceutical whistleblowers, we connect what the contract says with what the company actually paid for and reported. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.
You Know What the Contract Was Buying
If you worked on a generic launch, a supply agreement or the valuation behind a payment, talk with our whistleblower experts about what the deal bought. We connect your knowledge of the business to the contracts and decisions, bring in pharmaceutical whistleblower lawyers with the expertise your evidence calls for, and stay beside you as the case develops.
